$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Effects of combined use of Alpelisib and Fulvestrant
2026-02-01 22:25:32
Check Details
Baricitinib/Alemin Standard Usage and Dosage Instructions
2026-02-01 22:25:32
Check Details
Tucatinib/tucatinib side effects and countermeasures
2026-02-01 22:25:32
Check Details
Alpelisib-Piqray latest quotation inquiry channels and methods
2026-02-01 22:25:32
Check Details
FDA approves selumetinib/coselumab for symptomatic NF-1-associated inoperable plexiform neurofibromas in children
2026-02-01 22:25:32
Check Details
Casdatifan/cabotinib is effective in pretreated ccRCC
2026-02-01 22:25:32
Check Details
Identification of biomarkers of lorlatinib/lorlatinib treatment resistance in patients with ALK-positive advanced non-small cell lung cancer
2026-02-01 22:25:32
Check Details
The specific price situation of Bosutinib
2026-02-01 22:25:32
Check Details
Will the disease develop crazily after discontinuing Upatinib/Refu?
2026-02-01 22:25:32
Check Details
What diseases can Nintedanib/Vigat mainly treat and who is it suitable for?
2026-02-01 22:25:32
Check Details
What are the specific effects of bimetinib/bemetinib?
2026-02-01 22:25:32
Check Details
Will Teclistamab-cqyv be included in medical insurance in 2025?
2026-02-01 22:25:32
Check Details
1
2
...
2157
2158
2159
2160
2161
2162
2163
...
10240
10241
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Momelotinib for Myelofibrosis: Spleen Response, Symptom Improvement and Efficacy Monitoring
2
Pirtobrutinib and Risks of Atrial Fibrillation and Bleeding: Mechanism, Data Interpretation and Monitoring
3
Weight Gain and Edema Management, Monitoring of Repotrectinib (Augtyro) During Treatment
4
Ixazomib (Ninlaro) Dosing Schedule, Missed Dose Management and Cycle Planning in 28‑Day Regimen
5
Ponatinib in the PACE Phase II Trial: Response Data in Resistant CML and Ph+ ALL
6
Selumetinib for NF1-Related Plexiform Neurofibromas: Time to Response and Response Assessment
7
How to Take Tucatinib (Tukysa): Dosing Schedule, Combination Use & Missed Dose Guidance
8
Ganaxolone Common Side Effects: Somnolence, Sedation and Safety Notes
9
Baxdrostat: Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor
10
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
11
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
12
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks